Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab + Pyrotinib plus Gemcitabine/Cisplatin in HER2-expressing Advanced Cholangiocarcinoma
ChiCTR2500096074Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inetetamab and pyrotinib in intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by Beijing Chaoyang Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
inetetamabpyrotinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on ChiCTR2500096074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096074.